Phản ứng khác biệt với liệu pháp nội tiết neoadjuvant ở phụ nữ Black/African American và White trong NCDB

DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A et al (2019) Breast cancer statistics, 2019. CA Cancer J Clin 69(6):438–451

Rauscher GH, Silva A, Pauls H, Frasor J, Bonini MG, Hoskins K (2017) Racial disparity in survival from estrogen and progesterone receptor-positive breast cancer: implications for reducing breast cancer mortality disparities. Breast Cancer Res Treat 163(2):321–330

Vidal G, Bursac Z, Miranda-Carboni G, White-Means S, Starlard-Davenport A (2017) Racial disparities in survival outcomes by breast tumor subtype among African American women in Memphis, Tennessee. Cancer Med 6(7):1776–1786

Kim HS, Yoo TK, Park WC, Chae BJ (2019) Potential benefits of neoadjuvant chemotherapy in clinically node-positive luminal subtype(-) breast cancer. J Breast Cancer 22(3):412–424

Hoskins K, Danciu OC, Gadi VK, Simons Y, Blumencranz LE, Kling H et al (2021) Disparities within luminal breast cancer: clinical and molecular features of African American and non-Hispanic white patients. J Clin Oncol 39(15_suppl):1009

Barchiesi G, Mazzotta M, Krasniqi E, Pizzuti L, Marinelli D, Capomolla E et al (2020) Neoadjuvant endocrine therapy in breast cancer: current knowledge and future perspectives. Int J Mol Sci 21(10):3528

Cao L, Sugumar K, Keller E, Li P, Rock L, Simpson A et al (2021) Neoadjuvant endocrine therapy as an alternative to neoadjuvant chemotherapy among hormone receptor-positive breast cancer patients: pathologic and surgical outcomes. Ann Surg Oncol 28(10):5730–5741

Park KU, Gregory M, Bazan J, Lustberg M, Rosenberg S, Blinder V et al (2021) Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic. Breast Cancer Res Treat 188(1):249–258

Madigan LI, Dinh P, Graham JD (2020) Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women—a literature review and proposed guidelines. Breast Cancer Res 22(1):77

Siddharth S, Sharma D (2018) Racial disparity and triple-negative breast cancer in African-American women: a multifaceted affair between obesity, biology, and socioeconomic determinants. Cancers (Basel) 10(12):514

Lovejoy LA, Shriver CD, Haricharan S, Ellsworth RE (2023) Survival disparities in US Black compared to White women with hormone receptor positive-HER2 negative breast cancer. Int J Environ Res Public Health 20(4):2903

Hahn KM, Bondy ML, Selvan M, Lund MJ, Liff JM, Flagg EW et al (2007) Factors associated with advanced disease stage at diagnosis in a population-based study of patients with newly diagnosed breast cancer. Am J Epidemiol 166(9):1035–1044

Southerland VA, Brauer M, Mohegh A, Hammer MS, van Donkelaar A, Martin RV et al (2022) Global urban temporal trends in fine particulate matter (PM(2.5)) and attributable health burdens: estimates from global datasets. Lancet Planet Health 6(2):e139–e146

Ashing KT, Jones V, Bedell F, Phillips T, Erhunmwunsee L (2022) Calling attention to the role of race-driven societal determinants of health on aggressive tumor biology: a focus on Black Americans. JCO Oncol Pract 18(1):15–22

Fong AJ, Lafaro K, Ituarte PHG, Fong Y (2021) Association of living in urban food deserts with mortality from breast and colorectal cancer. Ann Surg Oncol 28(3):1311–1319

Moy B, Tu D, Pater JL, Ingle JN, Shepherd LE, Whelan TJ et al (2006) Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer. Ann Oncol 17(11):1637–1643

Zhao F, Copley B, Niu Q, Liu F, Johnson JA, Sutton T et al (2021) Racial disparities in survival outcomes among breast cancer patients by molecular subtypes. Breast Cancer Res Treat 185(3):841–849

Benefield HC, Reeder-Hayes KE, Nichols HB, Calhoun BC, Love MI, Kirk EL et al (2021) Outcomes of hormone-receptor positive, HER2-negative breast cancers by race and tumor biological features. JNCI Cancer Spectr. https://doi.org/10.1093/jncics/pkaa072

Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E et al (2014) Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol 32(25):2794–2803

Pistilli B, Lohrisch C, Sheade J, Fleming GF (2022) Personalizing adjuvant endocrine therapy for early-stage hormone receptor-positive breast cancer. Am Soc Clin Oncol Educ Book 42:1–13

Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P et al (2017) 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377(19):1836–1846

Li L, Chang B, Jiang X, Fan X, Li Y, Li T et al (2018) Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer. BMC Cancer 18(1):977

Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ et al (2016) Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol 2(11):1477–1486

Johnson K, Sarma D, Hwang ES (2015) Lobular breast cancer series: imaging. Breast Cancer Res 17(1):94

Selove R, Kilbourne B, Fadden MK, Sanderson M, Foster M, Offodile R et al (2016) Time from screening mammography to biopsy and from biopsy to breast cancer treatment among black and white, women Medicare beneficiaries not participating in a health maintenance organization. Womens Health Issues 26(6):642–647

Eaglehouse YL, Georg MW, Shriver CD, Zhu K (2019) Racial differences in time to breast cancer surgery and overall survival in the US Military Health System. JAMA Surg 154(3):e185113

Wheeler SB, Spencer J, Pinheiro LC, Murphy CC, Earp JA, Carey L et al (2019) Endocrine therapy nonadherence and discontinuation in Black and White women. J Natl Cancer Inst 111(5):498–508